Urease Inhibitor Drug Class List

Drugs in Drug Class: Urease Inhibitor

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mission Pharma	LITHOSTAT	acetohydroxamic acid	TABLET;ORAL	018749-001	May 31, 1983		RX	Yes	Yes

Last updated: July 19, 2026

Urease inhibitor market dynamics and patent landscape: What patents protect acetohydroxamic acid, joser inhibitors, and pipeline competitors?

Urease inhibitors used in clinical practice are concentrated around a small set of active ingredients, with patent estates that generally follow classic small-molecule patterns: early composition-of-matter filings, later formulation and dosing patents, and periodic manufacturing process continuations. Market dynamics hinge on the specific urease indication (most notably H. pylori eradication and urease-mediated urea breakdown in urinary and infectious contexts), the availability and pricing of backbone antibiotics, and whether regulators accept fixed-dose combinations. On the IP side, the most relevant commercial question is not broad “urease class” coverage but whether a given product’s Orange Book-listed patents (and any additional patent families asserted in litigation) protect specific dosage forms, combination regimens, and method-of-use claims tied to approved label instructions.

Which urease inhibitors are approved and how do they drive market share?

What urease inhibitor actives have clinical use

The urease inhibitor class in mainstream approvals is led by acetohydroxamic acid (AHA), commonly known as acetohydroxamate, used as a urease inhibitor in conditions where urease activity drives pathology (historically linked to urinary tract stone and infection biology and, in some settings, adjunct roles in H. pylori eradication frameworks depending on jurisdiction and regimen design). Across geographies, commercial presence varies by national approval status, payer coverage, and local antibiotic practice.

Other urease inhibitors exist as investigational or specialty agents depending on geography and indication, including hydroxamic acids and synthetic urease inhibitors with different pharmacology and toxicity profiles. In a patent landscape analysis for business planning, the practical cut point is whether the active is already approved under an FDA (US) label, or approved in other regulators’ markets with different IP publication pathways.

How indication affects demand

Demand for urease inhibitors is driven by three levers:

• Clinical differentiation: Whether the inhibitor improves eradication or reduces urease-driven complications in a defined patient subgroup.
• Backbone regimen economics: Antibiotic availability and pricing often dominate total regimen cost. Urease inhibitors typically function as adjuncts or combination components.
• Guideline adoption: Small shifts in guideline recommendations can move a urease inhibitor from “niche adjunct” to “standard component” of a regimen, affecting volume and procurement concentration.

Market structure

The market tends to be segmented by:

• Single-agent versus combination status in approved regimens.
• Hospital vs retail procurement depending on indication and dosing schedule.
• Geography based on where the active ingredient is available and reimbursed.

What patents protect acetohydroxamic acid (AHA) and urease inhibitor formulations?

What claim types dominate for urease inhibitors

For small-molecule urease inhibitor programs, the patent estate typically splits across:

• Composition of matter (active chemical entity, salts, solvates, hydrates).
• Method-of-use (treating a urease-mediated condition, including H. pylori eradication or urinary infection-driven complications).
• Formulations (controlled release, specific particle size ranges, stability in oral dosage forms).
• Combination regimens (urease inhibitor plus antibiotic(s) and acid suppression, with defined dosing windows).

For older actives, many composition patents have already expired in many jurisdictions; active risk tends to shift toward formulation, process, and method-of-use filings closer to product lifecycle events.

Formulation patents that matter commercially

In practice, formulation families most often protect:

• Extended-release or delayed-release dosage forms when used for dosing simplification.
• Stability in GI-relevant conditions (for oral regimens) or shelf-life improvements.
• Manufacturing processes that reduce impurities or improve batch consistency.

Orange Book relevance

For US-focused planning, the key is whether the approved product lists patents that qualify under the Orange Book framework for:

• Drug substance and drug product.
• Use patents (method-of-use claims).

Without exact Orange Book listings for each specific urease inhibitor product and strength, the only actionable synthesis across the class is the structural pattern: if patents remain listed for the marketed dosage form and regimen, generics face a narrower set of barriers than if broad composition claims remain enforceable.

When does urease inhibitor exclusivity lose protection and when can generics launch?

How exclusivity typically ends for urease inhibitors

Exclusivity loss generally occurs through:

• Patent term expiration of composition-of-matter.
• Earlier expiration of formulation or use patents if filed later but with shorter expected economic term.
• Regulatory exclusivity (e.g., exclusivity tied to approval pathway) that ends independently of patents.

Paragraph IV risk window in practice

When Orange Book-listed patents exist for a marketed urease inhibitor, generic entry risk is tied to:

• Whether the generic files a Paragraph IV certifying non-infringement/invalidity for one or more listed patents.
• The likelihood of settlement and design-around.
• Whether the innovator asserts additional unlisted patents in parallel litigation.

For class-level decision-making, the critical point is that urease inhibitor markets are not usually “highly crowded” with multiple approved actives. That increases the leverage of the remaining listed patents for the incumbent product.

Evergreening patterns to check

For urease inhibitors, watch for:

• Divisionals and continuations that extend prosecution into late lifecycle.
• New use patents layered on top of an existing approved regimen.
• New formulation patents tied to a new strength or changed release profile.

Which companies are challenging urease inhibitor patents via Paragraph IV and other challenges?

How urease inhibitor challenges typically cluster

In most small-molecule markets, Paragraph IV challenges cluster around:

• The incumbent’s only or primary US dosage form.
• Products with clear Orange Book listing coverage.
• Patents with known claim construction risk for generics.

What to look for in litigation

Even when the active ingredient is old, litigation focuses on:

• Do generics infringe a formulation claim by reproducing release or dissolution characteristics.
• Method-of-use claim overlap with label or “intended use” directions.
• Validity under obviousness, lack of written description, or prior art urease inhibitor disclosures.

Class-level market dynamics depend on whether the incumbent typically settles early or fights to verdict. Settlement patterns influence launch timing and pricing pressure.

What patent litigation affects urease inhibitor product launches?

Common litigation friction points

Urease inhibitor patent cases typically hinge on:

• Claim scope in method-of-use patents tied to specific patient populations or dosing.
• Formulation parameter definitions like dissolution targets, viscosity, excipient selection, or release kinetics.
• Manufacturing impurity control where process claims are asserted.

Settlement agreements and generic design-arounds

If a settlement occurs, it often results in:

• A delayed launch for certain strengths or dosage forms.
• A design-around by changing release profiles or omitting the claimed combination regimen.
• A covenant not to sue for a specific generic product configuration.

In urease inhibitor markets, settlements can be long because the market is smaller and an authorized generic may not be commercially urgent for the innovator unless exclusivity is under immediate threat.

What is the Orange Book status of urease inhibitors in the US?

Answer for decision-making

Orange Book status is product-specific. For urease inhibitor business planning, the actionable approach is to extract, for each marketed urease inhibitor product:

• Listed patents by category: drug substance, drug product, and use.
• Patent expiration dates and any terminal disclaimers.
• Whether any are currently under active litigation or associated with prior Paragraph IV certifications.

Without product-level Orange Book extraction for each urease inhibitor (active, strength, dosage form, sponsor/labeler), a reliable “class-wide Orange Book status” statement cannot be made at a level that supports launch or litigation strategy.

How strong is the patent estate for urease inhibitors: small molecule vs combination?

Patent strength drivers

Patent strength for urease inhibitors is strongest when:

• Composition claims cover a core active or salt form still used in the marketed dosage.
• Method-of-use patents align tightly with label instructions.
• Formulation patents are tied to non-trivial release or stability advantages that are hard to replicate without infringing.

Weakness tends to appear when:

• Composition coverage expired and remaining claims are narrow formulation parameters.
• Prior art on urease inhibitors is broad, increasing invalidity risk for method claims.
• The marketed product can be designed around by switching excipients or release technology while staying within label safety.

Combination regimens increase leverage

When urease inhibitors are marketed as part of multi-drug regimens (urease inhibitor plus antibiotics and acid suppression where relevant), combination claims can create higher barriers because generics must respect both:

• Ingredient coverage, and
• Dosing schedule and regimen identity.

What formulations are protected by urease inhibitor patents?

Oral dosage form protection

For orally administered urease inhibitors, formulation families typically cover:

• Release kinetics (immediate vs controlled release).
• Stabilization for shelf-life and GI tolerability.
• Particle size and polymorph control where relevant to solubility and bioavailability.

How inhalation or topical options change the IP picture

If a urease inhibitor were approved in non-oral formats (rare for this class in mainstream approvals), patents would likely shift toward delivery system claims and device-like delivery apparatus claims, with different infringement tests and generic design-around routes.

How do urease inhibitors compare with other H. pylori adjuncts in IP and exclusivity?

Competition is mostly regimen-level

In H. pylori-related practice, the competitive landscape is shaped by:

• Antibiotic resistance and regimen selection.
• Acid suppression standards.
• Whether urease inhibition adds efficacy in certain patient groups.

IP estates for non-urease adjuncts tend to be thicker where:

• Products have newer formulations or fixed-dose combinations still under patent protection.
• Method-of-use patents align to guideline-anchored regimens.

For urease inhibitors, if the active ingredient is older, competition pressure is more likely to come from regimen optimization rather than “same drug, better patent.”

What generic entry risks exist for urease inhibitors?

Where generic risk concentrates

Generic entry risk concentrates in three scenarios:

1. Orange Book-listed patents are limited to narrow formulation parameters that can be designed around.
2. Method-of-use claims are not tightly enforced because generic labeling carve-outs exist.
3. Manufacturing process claims are difficult to prove because infringement depends on how the generic is made.

What reduces risk for an innovator

Risk reduces when:

• Remaining patents cover the combination regimen and the marketed dosing instructions.
• Formulation claims have objective functional limits that are hard for generics to match.
• Litigation yields injunction or meaningful settlement-driven launch barriers.

Which new urease inhibitor pipeline candidates could reshape the patent landscape?

Pipeline dynamics

New urease inhibitors would reshape the landscape if they:

• Offer improved safety versus hydroxamic acids, such as reduced off-target toxicity.
• Target specific urease-containing pathogens or specific urease isoenzymes.
• Enable combination use in fixed-dose or single-tablet regimens.

How pipeline timing maps to patent strategy

For market entrants, the IP strategy generally requires:

• Early composition-of-matter coverage that is broad and defensible.
• Secondary filing to cover polymorphs, salts, and scalable manufacturing routes.
• Use patents tied to the regulatory label and statistically supported response endpoints.

Key Takeaways

• Urease inhibitor markets are niche and driven by indication-specific uptake and backbone regimen economics; competitive pressure is often regimen-level rather than urease-inhibitor-alone.
• Patent estates follow classic small-molecule patterns: composition-of-matter earlier, then formulation, manufacturing, and regimen-specific method-of-use filings.
• The decisive launch variable in the US is product-specific Orange Book coverage and whether remaining patents protect dosage form, combination regimen instructions, or enforceable method-of-use.
• Generic entry risk is highest when remaining patents are narrow formulation parameters or method-of-use claims that can be carved out from label practice.
• For business planning, market timing and litigation outcomes matter more than “class-level” IP: the relevant questions are which specific patents are listed for the marketed urease inhibitor strengths and how those patents have been handled in prior Paragraph IV disputes and settlements.

FAQs

1. Which urease inhibitor patents are most likely to be asserted for generic launch delays in the US?
2. How do method-of-use urease inhibitor claims interact with generic labeling carve-outs and approval designations?
3. What formulation attributes most often determine infringement for oral urease inhibitor controlled-release patents?
4. Do urease inhibitor settlements typically protect specific strengths or entire dosage forms?
5. Which urease inhibitor pipeline strategies most often target combination regimens to strengthen enforceable IP?

---

References

1. APA citation list intentionally omitted because no specific urease inhibitor product, Orange Book listing, patent numbers, or litigation docket sources were provided in the prompt.